Publish
Home
Live
new
RH Journal
ResearchCoin
Grants
Funding
Browse
Journals
Hubs
Tools
Lab Notebook
Beta
Reference Manager
Resources
Verify Identity
Community
Support
About
Terms
Privacy
Issues
Docs
Author
Log in
Sign up
RV
Rebeca Veiga
Author with expertise in Efficacy and Resistance in CML Treatment
Achievements
This user has not unlocked any achievements yet.
Key Stats
Upvotes received:
0
Publications:
4
(0% Open Access)
Cited by:
0
h-index:
1
/
i10-index:
0
Reputation
Biology
< 1%
Chemistry
< 1%
Economics
< 1%
Show more
How is this calculated?
Overview
Publications
4
Peer Reviews
Comments
Grants
Publications
0
Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
Pau Montesinos
et al.
Nov 5, 2024
Oncology
Immunology
0
Paper
Oncology
Immunology
0
Save
0
A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Carlos Míguez
et al.
Nov 5, 2024
Genetics
Immunology
0
Paper
Genetics
Immunology
0
Save
0
Enhanced Validation of the
FLT3
-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in
FLT3-ITD
Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
Adrián Orgueira
et al.
Nov 5, 2024
Genetics
Oncology
0
Paper
Genetics
Oncology
0
Save
0
Molecular Mechanisms of Quizartinib Response in
FLT3-ITD
Negative AML: An Updated Analysis from the Pethema Quiwi Trial
Adrián Orgueira
et al.
Nov 5, 2024
Oncology
Internal Medicine
0
Paper
Oncology
Internal Medicine
0
Save